![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: APOE |
Gene summary for APOE |
![]() |
Gene information | Species | Human | Gene symbol | APOE | Gene ID | 348 |
Gene name | apolipoprotein E | |
Gene Alias | AD2 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A0S2Z3D5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
348 | APOE | GSM4909281 | Human | Breast | IDC | 8.80e-42 | 9.22e-01 | 0.21 |
348 | APOE | GSM4909285 | Human | Breast | IDC | 1.34e-08 | 3.05e-01 | 0.21 |
348 | APOE | GSM4909293 | Human | Breast | IDC | 3.22e-08 | -2.39e-01 | 0.1581 |
348 | APOE | GSM4909295 | Human | Breast | IDC | 3.40e-02 | 3.39e-01 | 0.0898 |
348 | APOE | GSM4909296 | Human | Breast | IDC | 2.47e-04 | -2.22e-01 | 0.1524 |
348 | APOE | GSM4909297 | Human | Breast | IDC | 5.55e-07 | -2.39e-01 | 0.1517 |
348 | APOE | GSM4909299 | Human | Breast | IDC | 1.11e-08 | 5.00e-01 | 0.035 |
348 | APOE | GSM4909302 | Human | Breast | IDC | 1.27e-04 | 3.13e-01 | 0.1545 |
348 | APOE | GSM4909309 | Human | Breast | IDC | 7.67e-06 | 3.72e-01 | 0.0483 |
348 | APOE | GSM4909311 | Human | Breast | IDC | 2.02e-07 | -2.01e-01 | 0.1534 |
348 | APOE | GSM4909312 | Human | Breast | IDC | 7.71e-11 | -2.65e-01 | 0.1552 |
348 | APOE | GSM4909315 | Human | Breast | IDC | 5.71e-08 | -2.59e-01 | 0.21 |
348 | APOE | GSM4909319 | Human | Breast | IDC | 5.14e-08 | 3.05e-02 | 0.1563 |
348 | APOE | GSM4909321 | Human | Breast | IDC | 2.05e-08 | -2.64e-01 | 0.1559 |
348 | APOE | NCCBC14 | Human | Breast | DCIS | 1.43e-24 | 1.00e+00 | 0.2021 |
348 | APOE | NCCBC2 | Human | Breast | DCIS | 2.85e-05 | 6.98e-01 | 0.1554 |
348 | APOE | NCCBC3 | Human | Breast | DCIS | 2.21e-44 | 1.08e+00 | 0.1198 |
348 | APOE | NCCBC5 | Human | Breast | DCIS | 1.30e-09 | 5.49e-01 | 0.2046 |
348 | APOE | P1 | Human | Breast | IDC | 1.21e-03 | 2.27e-01 | 0.1527 |
348 | APOE | DCIS2 | Human | Breast | DCIS | 1.29e-08 | -4.91e-02 | 0.0085 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00358218 | Oral cavity | OSCC | modulation of process of other organism | 64/7305 | 106/18723 | 6.70e-06 | 7.36e-05 | 64 |
GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
GO:00518517 | Oral cavity | OSCC | modulation by host of symbiont process | 40/7305 | 60/18723 | 1.32e-05 | 1.33e-04 | 40 |
GO:00450884 | Oral cavity | OSCC | regulation of innate immune response | 116/7305 | 218/18723 | 1.36e-05 | 1.37e-04 | 116 |
GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
GO:00434073 | Oral cavity | OSCC | negative regulation of MAP kinase activity | 39/7305 | 59/18723 | 2.28e-05 | 2.16e-04 | 39 |
GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
GO:000166719 | Oral cavity | OSCC | ameboidal-type cell migration | 228/7305 | 475/18723 | 3.46e-05 | 3.10e-04 | 228 |
GO:004580710 | Oral cavity | OSCC | positive regulation of endocytosis | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
GO:00421582 | Oral cavity | OSCC | lipoprotein biosynthetic process | 57/7305 | 96/18723 | 4.17e-05 | 3.61e-04 | 57 |
GO:004352310 | Oral cavity | OSCC | regulation of neuron apoptotic process | 111/7305 | 212/18723 | 5.12e-05 | 4.27e-04 | 111 |
GO:000689810 | Oral cavity | OSCC | receptor-mediated endocytosis | 125/7305 | 244/18723 | 6.56e-05 | 5.32e-04 | 125 |
GO:00072669 | Oral cavity | OSCC | Rho protein signal transduction | 76/7305 | 137/18723 | 6.64e-05 | 5.37e-04 | 76 |
GO:00336194 | Oral cavity | OSCC | membrane protein proteolysis | 37/7305 | 57/18723 | 6.66e-05 | 5.38e-04 | 37 |
GO:00461652 | Oral cavity | OSCC | alcohol biosynthetic process | 77/7305 | 140/18723 | 8.77e-05 | 6.70e-04 | 77 |
GO:001063118 | Oral cavity | OSCC | epithelial cell migration | 174/7305 | 357/18723 | 1.04e-04 | 7.70e-04 | 174 |
GO:006082810 | Oral cavity | OSCC | regulation of canonical Wnt signaling pathway | 128/7305 | 253/18723 | 1.11e-04 | 8.16e-04 | 128 |
GO:009013218 | Oral cavity | OSCC | epithelium migration | 175/7305 | 360/18723 | 1.18e-04 | 8.54e-04 | 175 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501043 | Breast | DCIS | Alzheimer disease | 105/846 | 384/8465 | 3.23e-23 | 1.49e-21 | 1.10e-21 | 105 |
hsa0501053 | Breast | DCIS | Alzheimer disease | 105/846 | 384/8465 | 3.23e-23 | 1.49e-21 | 1.10e-21 | 105 |
hsa0501020 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
hsa05010110 | Endometrium | AEH | Alzheimer disease | 124/1197 | 384/8465 | 1.20e-20 | 3.91e-19 | 2.86e-19 | 124 |
hsa0501025 | Endometrium | EEC | Alzheimer disease | 126/1237 | 384/8465 | 2.25e-20 | 7.40e-19 | 5.52e-19 | 126 |
hsa0501035 | Endometrium | EEC | Alzheimer disease | 126/1237 | 384/8465 | 2.25e-20 | 7.40e-19 | 5.52e-19 | 126 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa049796 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa0497911 | Liver | NAFLD | Cholesterol metabolism | 20/1043 | 51/8465 | 9.73e-07 | 4.56e-05 | 3.67e-05 | 20 |
hsa049792 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa049793 | Liver | Cirrhotic | Cholesterol metabolism | 30/2530 | 51/8465 | 1.59e-05 | 1.39e-04 | 8.60e-05 | 30 |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa0501028 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa05010112 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa0501029 | Oral cavity | LP | Alzheimer disease | 197/2418 | 384/8465 | 6.66e-22 | 3.69e-20 | 2.38e-20 | 197 |
hsa0501037 | Oral cavity | LP | Alzheimer disease | 197/2418 | 384/8465 | 6.66e-22 | 3.69e-20 | 2.38e-20 | 197 |
hsa0501045 | Oral cavity | EOLP | Alzheimer disease | 87/1218 | 384/8465 | 5.79e-06 | 3.67e-05 | 2.16e-05 | 87 |
hsa0501055 | Oral cavity | EOLP | Alzheimer disease | 87/1218 | 384/8465 | 5.79e-06 | 3.67e-05 | 2.16e-05 | 87 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APOE | SNV | Missense_Mutation | rs372938213 | c.350C>T | p.Ala117Val | p.A117V | P02649 | protein_coding | deleterious(0.03) | possibly_damaging(0.592) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
APOE | SNV | Missense_Mutation | novel | c.685N>C | p.Gly229Arg | p.G229R | P02649 | protein_coding | tolerated(0.24) | benign(0.11) | TCGA-5M-AAT4-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
APOE | SNV | Missense_Mutation | c.128N>T | p.Arg43Leu | p.R43L | P02649 | protein_coding | deleterious(0) | benign(0.006) | TCGA-AA-A02Y-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
APOE | SNV | Missense_Mutation | c.371N>T | p.Ala124Val | p.A124V | P02649 | protein_coding | deleterious(0.01) | possibly_damaging(0.524) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
APOE | SNV | Missense_Mutation | c.239C>T | p.Ala80Val | p.A80V | P02649 | protein_coding | tolerated(0.33) | benign(0) | TCGA-G4-6627-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
APOE | SNV | Missense_Mutation | novel | c.353N>T | p.Ala118Val | p.A118V | P02649 | protein_coding | tolerated(0.17) | possibly_damaging(0.842) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APOE | SNV | Missense_Mutation | novel | c.53N>A | p.Ala18Asp | p.A18D | P02649 | protein_coding | deleterious(0) | possibly_damaging(0.453) | TCGA-QS-A8F1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
APOE | SNV | Missense_Mutation | rs752790054 | c.167N>A | p.Arg56His | p.R56H | P02649 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
APOE | SNV | Missense_Mutation | rs762461580 | c.149G>A | p.Arg50His | p.R50H | P02649 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
APOE | SNV | Missense_Mutation | novel | c.270G>T | p.Lys90Asn | p.K90N | P02649 | protein_coding | tolerated(0.39) | benign(0.09) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
348 | APOE | DRUGGABLE GENOME | PREDNISONE | PREDNISONE | 3185288 | |
348 | APOE | DRUGGABLE GENOME | BUTHIONINE SULFOXIMINE | 12615656 | ||
348 | APOE | DRUGGABLE GENOME | LORAZEPAM | LORAZEPAM | 15699298 | |
348 | APOE | DRUGGABLE GENOME | hmg coa reductase inhibitors | |||
348 | APOE | DRUGGABLE GENOME | fenofibrate | FENOFIBRATE | 12042669 | |
348 | APOE | DRUGGABLE GENOME | VITAMIN E | 12076219 | ||
348 | APOE | DRUGGABLE GENOME | ritonavir | RITONAVIR | 17700364,15809899 | |
348 | APOE | DRUGGABLE GENOME | TRIAMCINOLONE | TRIAMCINOLONE | 9150415 | |
348 | APOE | DRUGGABLE GENOME | ACE INHIBITOR | 12105166,15585195 | ||
348 | APOE | DRUGGABLE GENOME | CORTICOSTEROIDS | 1903065 |
Page: 1 2 3 4 |